AstraZeneca and Daiichi Sankyo will talk to regulators about their promising new Phase III results for datopotamab deruxtecan (Dato-DXd) in the most common form of advanced breast cancer – but may have to hold on for overall survival results before filing.
The companies have revealed that the TROP2-targeted antibody-drug conjugate (ADC) hit its primary endpoint of progression-free survival (PFS) in the...



![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)

